Navigation Links
MIS/AMH ELISA Test

ProductsMIS/AMH ELISA Test
Company Diagnostic Systems Laboratories, Inc.
Item MIS/AMH ELISA Test
Features Inquire
Description Mullerian Inhibiting Substance (MIS), also known as Anti-Mullerian Inhibiting Substance (AMH), is a glycoprotein dimer composed of two 72 kDa monomers linked by disulfide bridges (1). MIS/AMH belongs to the transforming growth factor-? (TGF-?) superfamily which includes TGF-? and the various inhibin and activin glycoproteins (2). All members of this superfamily are dimeric glycoproteins, and all are involved in the regulation of tissue growth and differentiation. The human gene coding for MIS/AMH has been sequenced and isolated, and is located on the short arm of chromosome 19 (3). The structure of a specific receptor for MIS/AMH has also been isolated and characterized (4).

MIS/AMH is produced by the Sertoli cells of the testis in the male, and by ovarian granulosa cells in the female. During embryonic development in males, secretion of MIS/AMH from testicular Sertoli cells is essential for the regression of the Mullerian ducts, and thus the normal development of the male reproductive tract (5). The Mullerian ducts are the primordium for the uterus, Fallopian tubes and upper vagina in the female. In the male, secretion of MIS/AMH by the Sertoli cells commences during embryogenesis and continues throughout life. Levels drop following puberty, decreasing slowly to a relatively low post-puberty value (2). In the female, serum MIS/AMH is undetectable using immunoassay until the onset of puberty. Thereafter, circulating MIS/AMH is maintained at relatively low levels until menopause, at which time MIS/AMH falls again to undetectable levels (as measured by immunoassay).

Potential clinical applications for a specific MIS/AMH assay include: the investigation of ovarian reserve and the perimenopausal transition in women; the detection and management of granulosa cell tumors; the diagnosis of precocious puberty and conversely, its delayed onset in the young; the differential diagnosis of intersex disorders; the diagnosis of cryptoorchidism and anorchidism, and the evaluation of male gonadal function at all ages (2).

  1. Picard JY, Josso N Mol Cell Endocrinol 34: 23-29, 1984.
  2. Teixeira J et al. Endocrine Reviews 22: 657-674, 2001.
  3. Picard JY et al. Proc Natl Acad Sci 83: 5464-5468, 1986.
  4. di Clemente N et al. Mol Endocrinol 8: 1006-1020, 1994.
  5. Picon R Arch Anat Microsc Morphol Exp 58: 1-19, 1969.
  6. Hudson PL et al. J Clin Endocrinol Metab 70: 16-22, 1990.
Info Diagnostic Systems Laboratories, Inc.
Customer Service: (800) 231-7970
Web site: http://www.dslabs.com

Related medicine products :

1. Microplate ELISA Washers - Manual Microplate Washer
2. Microplate ELISA Washers - Automated Microplate Washer
3. Vitamin D 25-Hydroxy ELISA 026-AC-57F1 Bone and Mineral Metabolism
4. RELISA ANA Screening System
5. BioCheck hCG ELISA
6. Human Chorionic Gonadotropin (HCG) ELISA Kit
7. Human PSA ELISA Kit
8. Total PSA ELISA Test
9. Free PSA ELISA
10. PAP Microwell ELISA
11. Trinity Biotech Captia™ B. burgdorferi IgG/IgM ELISA
... maximum positioning flexibility while permitting the components to ... easy transport. The system has a small footprint ... at the same time offers the surgeon total ... camera and display of the Stealthstation Treon can ...
... system for ENT, cranial and spine ... preoperatively, critical zones visible during tracking. ... vision, one button freezes image, snapshot ... Microscope interface: tracks focal point of ...
...
...
Medicine Products:
(Date:9/2/2014)... 02, 2014 Becker's Healthcare is ... and Chief Information Officer Strategy Roundtables on November ... Becker's Hospital Review Chief Executive Officer and Chief ... health system Chief Executive Officers, Chief Financial Officers, ... system executives through high-quality continuing education, networking ...
(Date:9/2/2014)... BambooIndustry.com, an excellent company in the bamboo industry, has ... floors to celebrate the coming of autumn. To ... frequent callers, BambooIndustry.com launched a promotion for its newly ... floors, BambooIndustry.com provides many kinds of wonderful items for ... floors, click lock floors, wide plank floors and so ...
(Date:9/2/2014)... pm EDT): In a Viewpoint published today in the ... team of Boston researchers call for the implementation of ... United States. The researchers from the Friedman School of ... and Boston Children,s Hospital write that policies taxing nearly ... help people make meaningful dietary changes and substantially reduce ...
(Date:9/2/2014)... 2014 TCG, a leading government technology strategy ... one of the fastest-growing companies in America for the seventh ... was previously recognized in 2013, 2012, 2011, 2010, 2009, 2008, ... grown 86% from 2010 to 2013, ranking the company at ... in America - up 635 spots from 2013! More information ...
(Date:9/2/2014)... New York, NY (PRWEB) September 02, 2014 ... and other new blood thinners is growing at a ... ) continue to mount in courts around the U.S., ... published in American Journal of Medicine, within a year ... to be prescribed Xarelto as warfarin, a blood thinner ...
Breaking Medicine News(10 mins):Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 3Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 4Health News:Cheap Strand Woven Bamboo Floors For Autumn On Sale At BambooIndustry.com 2Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4
... that feeding tubes do not improve survival rates or ... their frequency of use varies widely across the states. ... surrounding the decision to place feeding tubes surgically are ... that often affects a patient,s ability to eat. In ...
... People with dementia may soon have improved oral hygiene ... four-year grant to Rita A. Jablonski, assistant professor of ... disease have all been linked to poor oral hygiene. ... for because they often are no longer able to ...
... to predict the risk of disease progression and response ... for high- and low-risk patients, but do not always ... a new analysis shows. In recent years, ... information for breast cancer. Dr Catherine Kelly from Mater ...
... COLUMBUS, Ohio In a rare and medically remarkable operation, ... Comprehensive Cancer Center Arthur G. James Cancer Hospital and ... left leg, hip and pelvis of a cancer patient, and ... completely rebuild the connection between his spine and remaining right ...
... 4 (HealthDay News) -- U.S. health officials issued final ... liquid over-the-counter drug products that are measured and dispensed ... The U.S. Food and Drug Administration developed the ... overdoses when using liquid over-the-counter (OTC) pain relievers, cold ...
... WEDNESDAY, May 4 (HealthDay News) -- A gene essential to ... heart defects that cause a major proportion of childhood death ... cardiac defects -- all malformations of the left ventricular outflow ... component may play a role. "It is estimated that ...
Cached Medicine News:Health News:Families need to know more about feeding tubes for elderly dementia patients 2Health News:Breast cancer multi-gene tests compared 2Health News:Breast cancer multi-gene tests compared 3Health News:Ohio State surgeons rebuild pelvis of cancer patient 2Health News:Ohio State surgeons rebuild pelvis of cancer patient 3Health News:FDA Issues Guidelines for Liquid OTC Medicines 2Health News:New Gene Linked to Congenital Heart Defects 2
(Date:9/2/2014)... España, September 2, 2014 ... fibrilación atrial muestran agentes antitrombóticos no utilizados óptimamente ... -- Las presentaciones de GARFIELD-AF en el ... tratamiento y los resultados de pacientes en riesgo ... --    Los datos de casi ...
(Date:9/2/2014)... Spain , September 2, 2014 ... at ESC CONGRESS 2014 provide insight into treatment ... in everyday clinical practice --   ... Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), ... that stroke prevention strategies for atrial fibrillation (AF) ...
(Date:9/2/2014)... VIEJO, Calif. , Sept. 2, 2014  Avanir Pharmaceuticals, ... management will present an overview of the company at the ... . , Presentation date: Tuesday September 9, ... A live webcast and 30-day archive of this ... About Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9